“We’re excited to be funding and working with Palisade Bio to address major unmet needs in #FSCD and #UlcerativeColitis,” said Andrés Hurtado Lorenzo, PhD, SVP of Translational Research and IBD Ventures at @CrohnsColitisFn. Learn more: https://t.co/AxDyWSQOBx $PALI

“We are honored to receive this strategic equity investment from the @CrohnsColitisFn through its IBD Ventures program,” said J.D. Finley, CEO of Palisade Bio. Read more: https://t.co/AxDyWSQOBx $PALI #FibrostenoticCrohnsDisease #FSCD #UlcerativeColitis

Palisade announced that @CrohnsColitisFn, through its IBD Ventures program, has approved a strategic equity investment of up to $500,000 in Palisade. The investment will support the continued clinical & mechanistic development of PALI-2108. Details: https://t.co/AxDyWSQOBx $PALI

“Securing this Japanese patent for PALI-2108 is an important milestone as we continue to strengthen the IP foundation for our #IBD portfolio,” said J.D. Finley, CEO of Palisade Bio. Learn more: https://t.co/Gmhnu0pPP1 $PALI #FibrostenoticCrohnsDisease #FSCD #UlcerativeColitis

Palisade announced that the Japan Patent Office has granted a key patent covering PALI-2108, the Company’s lead, gut-microbiota-activated PDE4 B/D inhibitor being advanced for #FibrostenoticCrohnsDisease & moderate to severe #UlcerativeColitis. https://t.co/Gmhnu0pPP1 $PALI #FSCD

#InCaseYouMissedIt: JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, Chief Medical Officer of Palisade Bio, participated in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference. Catch up on the replay here: https://t.co/RU3oHg1PFD $PALI #FSCD #UC

Tune-in today, December 4th at 10:30 AM ET for a fireside chat with JD Finley, Chief Executive Officer and Dr. Mitchell Jones, Chief Medical Officer of Palisade Bio, at the Piper Sandler 37th Annual Healthcare Conference: https://t.co/wV4drHCJgM $PALI

Dr. James Izanec, Palisade's newly appointed VP, Clinical Development, is a veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease. https://t.co/IGTRGleyZl $PALI

Palisade announced the appointment of James Izanec, MD, AGAF as VP, Clinical Development. Dr. Izanec is a physician–scientist with over two decades of clinical and drug development leadership spanning immunology, gastroenterology, and neuroscience. https://t.co/IGTRGleyZl $PALI

On Thursday, December 4th at 10:30 AM ET, Palisade CEO, JD Finley, and Chief Medical Officer, Dr. Mitchell Jones, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference. Register for the webcast here: https://t.co/wV4drHCJgM $PALI

We are deeply saddened by the passing of Professor Brian Feagan, a valued member of our Clinical Advisory Board and a visionary in inflammatory bowel disease research. Our thoughts are with his family, colleagues, and all who had the privilege of working with him.

JD Finley, Chief Executive Officer and Dr. Mitchell Jones, Chief Medical Officer of Palisade Bio, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 10:30 AM ET. For details: https://t.co/fiVuUtq4bJ $PALI

Ms. Skare joins $PALI with expertise spanning autoimmune, metabolic, gastrointestinal, and fibrotic diseases, with a track record of delivering programs from early development through regulatory approval, commercialization, and post-marketing submissions. https://t.co/7Qg9UlUudc

“We are thrilled to welcome Sharon to Palisade Bio,” said Dr. Mitchell Jones, MD, PhD, Chief Medical Officer of Palisade Bio. Read more about the appointment of Sharon Skare, PhD(c) as Vice President, Global Head of Clinical Operations: https://t.co/7Qg9UlUudc $PALI

Palisade announced the appointment of Sharon Skare, PhD(c) as VP, Global Head of Clinical Operations. Ms. Skare brings over 24 years of experience in clinical development across autoimmune, metabolic, cardiovascular, and gastrointestinal indications. https://t.co/7Qg9UlUudc $PALI

Data from the #FibrostenoticCrohnsDisease Phase 1b study, together with results from the Phase 1a/1b #UlcerativeColitis program, are expected to support Phase 2 IND submissions to the U.S. FDA in the first half of 2026. Read more: https://t.co/SHDNNSvOdU $PALI

PALI-2108 is the first dual-acting anti-inflammatory and anti-fibrotic candidate in development for #UlcerativeColitis and #FibrostenoticCrohnsDisease, a condition with no approved therapies. Learn about the Ph. 1b study of PALI-2108 for #FSCD: https://t.co/SHDNNSvOdU $PALI

“The initiation of patient dosing marks a significant milestone in our mission to address fibrostenotic complications in Crohn’s disease, an area with no current approved medical therapies.”— Dr. Jones, Palisade Chief Medical Officer. Learn more: https://t.co/SHDNNSvOdU $PALI

Palisade announced that the first patients have been dosed in its Phase 1b clinical study evaluating PALI-2108 for the treatment of #FibrostenoticCrohnsDisease. Topline data remains on track to be reported in the first quarter of 2026. For details: https://t.co/SHDNNSvOdU $PALI

“We remain committed to strengthening the intellectual property portfolio around PALI-2108 and are focused on advancing the development of this program," commented J.D. Finley, CEO of Palisade. Learn about our newly issued patent: https://t.co/pfDfKMbvHB $PALI